Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3383059 | 0.71 | UGT2B7 (0.37) | APLNRUGT2B7 | |
| SCHEMBL3384993 | 0.68 | UGT2B7 (0.39) | APLNRUGT2B7 | |
| Oxirane SCHEMBL11314996 | 0.67 | APLNR (0.36) | APLNRUGT2B7 | |
| SCHEMBL5246594 | 0.66 | APLNR (0.41) | APLNRUGT2B7 | |
| SCHEMBL11260869 | 0.66 | APLNR (0.41) | APLNRUGT2B7 | |
| SCHEMBL3385056 | 0.66 | APLNR (0.41) | APLNRUGT2B7 | |
| SCHEMBL10886237 | 0.61 | — | — | |
| SCHEMBL3152763 | 0.61 | — | — | |
| SCHEMBL10886248 | 0.61 | — | — | |
| SCHEMBL2832388 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1253135-B1 | Asymmetric copper complex and cyclopropanation reaction using the same | SUMITOMO CHEMICAL CO (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-6858559-B2 | Using copper complex containing oxazole molecules | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-02-22 | — | — | US | disclosed |
| US-20020177718-A1 | Asymmetric copper complex and cyclopropanation reaction using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1253135-A1 | Asymmetric copper complex and cyclopropanation reaction using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177718-A1 | Asymmetric copper complex and cyclopropanation reaction using the same | AOC3, AOC1, ACSL3 | APLNR 2723/4885UGT2B7 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.